Serum proteomics links suppression of tumor immunity to ancestry and lethal prostate cancer.
Serum proteomics links suppression of tumor immunity to ancestry and lethal prostate cancer.
复制标题
DOI:
10.1038/s41467-022-29235-2
复制
发表时间:
2022-04-01
影响因子:
16.6
通讯作者:
Ambs S
中科院分区:
文献类型:
--
作者:
Minas TZ;Candia J;Dorsey TH;Baker F;Tang W;Kiely M;Smith CJ;Zhang AL;Jordan SV;Obadi OM;Ajao A;Tettey Y;Biritwum RB;Adjei AA;Mensah JE;Hoover RN;Jenkins FJ;Kittles R;Hsing AW;Wang XW;Loffredo CA;Yates C;Cook MB;Ambs S
There is evidence that tumor immunobiology and immunotherapy response may differ between African American and European American prostate cancer patients. Here, we determine if men of African descent harbor a unique systemic immune-oncological signature and measure 82 circulating proteins in almost 3000 Ghanaian, African American, and European American men. Protein signatures for suppression of tumor immunity and chemotaxis are elevated in men of West African ancestry. Importantly, the suppression of tumor immunity protein signature associates with metastatic and lethal prostate cancer, pointing to clinical importance. Moreover, two markers, pleiotrophin and TNFRSF9, predict poor disease survival specifically among African American men. These findings indicate that immune-oncology marker profiles differ between men of African and European descent. These differences may contribute to the disproportionate burden of lethal prostate cancer in men of African ancestry. The elevated peripheral suppression of tumor immunity may have important implication for guidance of cancer therapy which could particularly benefit African American patients. Ancestry-related differences in immunobiology may explain the health disparities observed in prostate cancer patients, with men of African origin bearing the highest prostate cancer burden. By measuring immune-related proteins in serum samples, here the authors report that systemic cytokines linked to suppression of tumor immunity are upregulated in men of African ancestry and associated with reduced survival.
登录
查看更多内容
DOI:
10.1126/science.aao4227
发表时间:
2018-09-28
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Albrengues J;Shields MA;Ng D;Park CG;Ambrico A;Poindexter ME;Upadhyay P;Uyeminami DL;Pommier A;Küttner V;Bružas E;Maiorino L;Bautista C;Carmona EM;Gimotty PA;Fearon DT;Chang K;Lyons SK;Pinkerton KE;Trotman LC;Goldberg MS;Yeh JT;Egeblad M
通讯作者:
Egeblad M
影响因子:
2.1
作者:
Hardiman, Gary;Savage, Stephen J.;Gattoni-Celli, Sebastiano
通讯作者:
Gattoni-Celli, Sebastiano
影响因子:
8.8
作者:
Feng, Xiaoshuang;Song, Mingyang;Mucci, Lorelei A.
通讯作者:
Mucci, Lorelei A.
DOI:
10.1158/1078-0432.ccr-20-2925
发表时间:
2021-01-01
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
Awasthi S;Berglund A;Abraham-Miranda J;Rounbehler RJ;Kensler K;Serna A;Vidal A;You S;Freeman MR;Davicioni E;Liu Y;Karnes RJ;Klein EA;Den RB;Trock BJ;Campbell JD;Einstein DJ;Gupta R;Balk S;Lal P;Park JY;Cleveland JL;Rebbeck TR;Freedland SJ;Yamoah K
通讯作者:
Yamoah K
影响因子:
10.3
作者:
Kiely, Maeve;Milne, Ginger L.;Ambs, Stefan
通讯作者:
Ambs, Stefan